Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerLung cancer biomarkers, targeted therapies and clinical assaysRole of HER2 in NSCLCAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularThe minority report: targeting the rare oncogenes in NSCLCHER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approachesReview of the current targeted therapies for non-small-cell lung cancerTargeted therapies in development for non-small cell lung cancerCIViC databaseTargeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsHER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsThe Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung CancerBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivoA patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularRecent advances in personalized lung cancer medicineDevelopment of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortiumMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Targeted therapy in NSCLC driven by HER2 insertionsLung cancer molecular epidemiology in China: recent trendsPrevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung AdenocarcinomaLung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFRA systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivoThe frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Translating genomic information into clinical medicine: lung cancer as a paradigm.HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.New targetable oncogenes in non-small-cell lung cancer.Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
P2860
Q26738986-E6661166-9447-46B7-8DF3-6121105A1675Q26775396-F2FD2335-EFB0-4FBB-91A5-A4EFFB267304Q26781683-34A59C85-B020-4CE5-9C51-3A78A85A749CQ26797471-D40AF2F3-F6CE-445D-92BE-95242148FF29Q26799467-B693A814-3E71-47F7-93FB-75E6C1847BB4Q26828860-9768409C-79F0-4647-8C5B-FB460E447B71Q26851636-E75B3E5C-1F8B-43F2-89D8-4111A40513AFQ26866534-DDA837A1-51EF-4446-B4CF-6A93C5336847Q27015079-F83953DA-D72D-4DB7-8632-AA1B974E9C10Q27022852-B1A65473-1643-4D09-B185-4DA48781A2BBQ27612411-CB248959-0070-4716-8071-5B58EB968645Q27853154-10F395C7-71F5-47AD-883D-D70EEAC3CCD3Q27853242-68A91B06-03A1-4EEA-877B-6BA11CEE90DAQ27853282-FCB5CB79-1FB9-4BFC-BBE8-3D9F33680BCAQ28083446-A5C53183-33D5-466E-863F-A315011B5747Q28086768-828B958B-5ED4-4E80-9921-1E7DD6769861Q28395836-A1CB8F82-5285-4E99-9E93-49A6F5C4BB5FQ33560928-22017CEB-C4EC-46AF-BB1D-2E358A270EE1Q34104079-7BDDA59A-CBCC-4513-A8F8-843BAD20939EQ34118710-393642D0-8454-4F71-900E-5D17E28476FBQ34159011-3C13A2F4-42B1-4001-9A98-23D5C6D63DAEQ34678073-2F4F1A19-C939-4DF5-9209-3DB35BAAE4CFQ35053271-B9EB5B15-2C41-4A75-8DBC-5C908EB547B8Q35136424-DEABE6D8-5ED9-4F4B-B4E5-0ADEFDBD404AQ35200528-CBF7B057-8B13-45CF-93A3-F21376D252FEQ35200702-44374E6F-3CC5-4D3B-971B-4936B99CAFA1Q35671830-6EACE7E3-FC36-4B86-AD8B-51B940D0D0F3Q35741716-2257B14C-50B3-4571-BF21-DD07EBC0E349Q35782291-1E03DF6D-0DDF-40B1-B4F8-D1B62023C4B7Q35822882-10A46CF7-76C8-475D-8863-93DFEC4D8F17Q36266449-CAF57E2E-AAC9-497F-A614-3E78F9F0222DQ36354845-1D4746AF-5DFD-434B-A8AA-FC89300D51ACQ36423790-61156A8B-EDC1-4B05-A73D-87E49E97D45AQ36495936-88F08B73-5D8D-4C24-A30A-79361D7D3602Q36660677-AC1B1B51-E935-4DAE-AA56-A79FAA6B3D47Q36772036-89A40936-0DA2-4114-A7E2-ECB54329B428Q36785721-A0413222-A869-4DC1-8641-82EAAE2D51C9Q36999705-F549DC99-97BA-4C6A-82EB-D7B8056D8584Q37141350-A4210DEA-9E77-4C5D-BBB6-8AD2E478F822Q37246286-67551E90-8701-4DDD-95F1-AE1B88C31739
P2860
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@ast
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@en
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@nl
type
label
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@ast
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@en
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@nl
altLabel
Clinical activity of afatinib ...... the kinase domain of HER2/neu
@en
prefLabel
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@ast
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@en
Clinical activity of afatinib ...... the kinase domain of HER2/neu.
@nl
P2093
P921
P3181
P1433
P1476
Clinical activity of afatinib ...... the kinase domain of HER2/neu
@en
P2093
D Galdermans
D Schallier
H Everaert
L Decoster
P In't Veld
P304
P3181
P356
10.1016/J.LUNGCAN.2012.01.008
P407
P577
2012-02-10T00:00:00Z